Reviva Pharmaceuticals Holdings, Inc. (RVPH) P/E Ratio History
Deep ValueTrading at -0.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2019–2020
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Reviva Pharmaceuticals Holdings, Inc. (RVPH) trades at a price-to-earnings ratio of -0.1x, with a stock price of $0.66 and trailing twelve-month earnings per share of $-2.37.
The current P/E is 100% below its 5-year average of 33.8x. Over the past five years, RVPH's P/E has ranged from a low of 27.7x to a high of 39.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, RVPH trades at a 101% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, RVPH trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RVPH DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RVPH Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
RVPH P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 11.1 | - | +68% | |
| $2B | 7.1Lowest | 0.69 | +817%Best | |
| $7B | 10.9 | - | +264% | |
| $2B | 9.7 | 0.06Best | +40% | |
| $9B | 38.5 | - | -34% | |
| $32B | 24.4 | 0.60 | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
RVPH Historical P/E Data (2019–2020)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2020 Q1 | Feb 29 2020 | $211.20 | $5.41 | 39.0x | +15% |
| FY2019 Q4 | Nov 30 2019 | $208.80 | $6.50 | 32.1x | -5% |
| FY2019 Q3 | Aug 31 2019 | $207.00 | $7.48 | 27.7x | -18% |
| FY2019 Q2 | May 31 2019 | $204.80 | $5.61 | 36.5x | +8% |
Average P/E for displayed period: 33.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RVPH — Frequently Asked Questions
Quick answers to the most common questions about buying RVPH stock.
What is RVPH's P/E ratio?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) trailing twelve-month P/E ratio is -0.1x, based on TTM diluted EPS of $-2.37. The 5-year average P/E is 33.8x and the historical range spans 27.7x to 39.0x.
Is RVPH stock overvalued or undervalued?
RVPH trades at -0.1x P/E, below its 5-year average of 33.8x. At the 0th percentile of its historical range (27.7x–39.0x), the stock is priced at a discount to its own history.
Is RVPH stock expensive?
No, RVPH is not expensive on a historical basis. The current P/E of -0.1x is below the 5-year average of 33.8x and sits at the 0th percentile of its valuation range.
What is RVPH's historical P/E range?
Over the past 5 years, RVPH's P/E ratio has ranged from 27.7x to 39.0x, with a median of 36.5x and an average of 33.8x. The current P/E of -0.1x places the stock at the 0th percentile of this range. Full historical data spans 2019–2020.
How does RVPH's P/E compare to the S&P 500?
RVPH trades at -0.1x P/E versus the S&P 500 median of 25.3x. The 100% discount to the market suggests lower growth expectations or perceived higher risk.
How does RVPH's valuation compare to Healthcare peers?
Reviva Pharmaceuticals Holdings, Inc. P/E of -0.1x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is RVPH's PEG ratio?
RVPH PEG ratio is N/A, based on a P/E of -0.1x and EPS growth of 69.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is RVPH's earnings yield?
RVPH earnings yield is N/A, the inverse of its -0.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.